CN118678966A - 用于治疗或预防成人t细胞白血病的医药组合物 - Google Patents

用于治疗或预防成人t细胞白血病的医药组合物 Download PDF

Info

Publication number
CN118678966A
CN118678966A CN202380020568.7A CN202380020568A CN118678966A CN 118678966 A CN118678966 A CN 118678966A CN 202380020568 A CN202380020568 A CN 202380020568A CN 118678966 A CN118678966 A CN 118678966A
Authority
CN
China
Prior art keywords
hla
peptide
amino acid
peptides
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380020568.7A
Other languages
English (en)
Chinese (zh)
Inventor
内丸薰
中野和民
吉原庆子
福岛卓也
田中勇悦
加留部谦之辅
益崎裕章
大岛孝一
三好宽明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEC Corp
University of the Ryukyus NUC
Kurume University
University of Tokyo NUC
Original Assignee
NEC Corp
University of the Ryukyus NUC
Kurume University
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEC Corp, University of the Ryukyus NUC, Kurume University, University of Tokyo NUC filed Critical NEC Corp
Publication of CN118678966A publication Critical patent/CN118678966A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380020568.7A 2022-02-25 2023-02-24 用于治疗或预防成人t细胞白血病的医药组合物 Pending CN118678966A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-027480 2022-02-25
JP2022027480 2022-02-25
PCT/JP2023/006691 WO2023163094A1 (ja) 2022-02-25 2023-02-24 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
CN118678966A true CN118678966A (zh) 2024-09-20

Family

ID=87766096

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380020568.7A Pending CN118678966A (zh) 2022-02-25 2023-02-24 用于治疗或预防成人t细胞白血病的医药组合物

Country Status (5)

Country Link
US (1) US20250236642A1 (https=)
EP (1) EP4483894A4 (https=)
JP (2) JPWO2023163094A1 (https=)
CN (1) CN118678966A (https=)
WO (1) WO2023163094A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
EP1339871B1 (en) * 2000-08-15 2008-10-15 The Johns Hopkins University School Of Medicine Diagnosis and treatment of tumor-suppressor associated disorders
WO2004092373A1 (ja) * 2003-04-16 2004-10-28 Japan Science And Technology Agency Ｈｔｌｖ－ｉ特異的ｃｔｌ誘導活性ペプチド
WO2006004182A1 (ja) 2004-07-07 2006-01-12 Nec Corporation 配列予測システム
JP5176099B2 (ja) * 2004-09-27 2013-04-03 国立大学法人 東京医科歯科大学 ＨＬＡ−Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ
JP5131946B2 (ja) * 2005-09-13 2013-01-30 国立大学法人 東京大学 がんの診断、処置および／または予防、および／または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法
EP2069793B9 (en) * 2006-08-29 2017-08-16 Oxford BioTherapeutics Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
CN102341412B (zh) * 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
WO2012119989A2 (en) * 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
JP5999703B2 (ja) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
EP3925968A3 (en) * 2014-10-07 2022-03-02 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
EP3269726B1 (en) * 2015-03-09 2025-05-07 Nec Corporation Peptide derived from muc1, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cells
CN113388021A (zh) * 2015-03-09 2021-09-14 Cytlimic公司 源于gpc3的肽、使用其的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
CN109535231B (zh) * 2018-11-21 2021-03-19 温州医科大学附属第一医院 人T细胞病毒抗原蛋白Tax的CTL特异性识别表位及其应用
JP7593242B2 (ja) 2020-07-29 2024-12-03 Jsr株式会社 液晶配向剤、液晶配向膜及び液晶素子
JPWO2022244801A1 (https=) * 2021-05-19 2022-11-24

Also Published As

Publication number Publication date
US20250236642A1 (en) 2025-07-24
EP4483894A4 (en) 2026-04-29
EP4483894A1 (en) 2025-01-01
JP2025172927A (ja) 2025-11-26
JPWO2023163094A1 (https=) 2023-08-31
WO2023163094A1 (ja) 2023-08-31

Similar Documents

Publication Publication Date Title
US10239916B2 (en) Controlled modulation of amino acid side chain length of peptide antigens
US10875900B2 (en) Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using same, immunity inducer, and method for producing antigen-presenting cells
CA2886552A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
US12448413B2 (en) HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell
ES2316191T3 (es) Nueva proteina antigenica tumoral sart-3 y peptido antigenico tumoral de la misma.
CN118678966A (zh) 用于治疗或预防成人t细胞白血病的医药组合物
TW201639868A (zh) 來自muc1之胜肽、使用此胜肽之用於治療或預防癌症之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination